-
CycleTrack and SDN are teaming up to make medical school admissions more transparent and accessible! Read the announcement to learn how we’re supporting the future of CycleTrack’s free application-tracking tools .
stroke
Started by medicineman1
Get help with your application
Use all the free resources available to you from SDN: articles, guides, expert advising, forums discussions, and school research.
www.pubmed.org
Search for "stroke".
Seriously. That generates 133,000+ articles (today).
You want population-based? Check out PROFESS. That's brand-spanking new. Puts Aggrenox in the corner.
Molecular genetics? Try Prog Neurobiol. 2008 Apr 26. Interesting article on neural cell progenitor therapy for stroke.
Radiology? How about Stroke. 2008 Jun 26. Great article on DWI changes in TGA.
Enjoy.
Search for "stroke".
Seriously. That generates 133,000+ articles (today).
You want population-based? Check out PROFESS. That's brand-spanking new. Puts Aggrenox in the corner.
Molecular genetics? Try Prog Neurobiol. 2008 Apr 26. Interesting article on neural cell progenitor therapy for stroke.
Radiology? How about Stroke. 2008 Jun 26. Great article on DWI changes in TGA.
Enjoy.
PRoFESS was meant to compare telmisartan with placebo, as well as to compare ASA+dipyridamol vs. clopidogrel in rates of secondary stroke.
The Aggrenox arm had no significant difference in secondary stroke prevention than the Plavix arm. Additionally, there was no significant difference in hemorrhagic complications between the two arms. Aggrenox was more poorly tolerated, with higher complaints of side-effects, and poorer adherence to the trial regimen.
If Plavix has the same risk-benefit ratio as Aggrenox, and your patient is more likely to tolerate and adhere to the treatment regimen, then why prescribe Aggrenox at all?
The Aggrenox arm had no significant difference in secondary stroke prevention than the Plavix arm. Additionally, there was no significant difference in hemorrhagic complications between the two arms. Aggrenox was more poorly tolerated, with higher complaints of side-effects, and poorer adherence to the trial regimen.
If Plavix has the same risk-benefit ratio as Aggrenox, and your patient is more likely to tolerate and adhere to the treatment regimen, then why prescribe Aggrenox at all?
